

# Biosimilars Overview

## Quick Start Guide


July 2022




# What is Biosimilars?

Biosimilars is part of a suite of Clarivate applications on our Disease Insights platform. It sizes the potential opportunity and evaluates the disruptive effects of biosimilars could have on the pharma industry. Biosimilars is based on surveys of over 500 physician specialists, 60 US payers, and country-specific interviews with 10 EU5 payers.

- **Landscape** provides insights that are critical to understanding the biosimilars landscape for all therapeutic areas.
- **Detailed & expanded analysis** provides in-depth analysis within select core research modules for the four leading therapeutic areas for biosimilars.




# Summary of Biosimilars on Insights Platform




Oncology	Immunology	Endocrinology
Nephrology	Ophthalmology	Respiratory

# Get started using Biosimilars



1. Click on the “Disease, Company & Drug Insights” link to launch the Disease, Company & Insights platform.

2. Click Biosimilars link and then select Biosimilars At a Glance link.



# Biosimilars Report At a Glance

1. The At a Glance page displays all of the modules available within Biosimilars:

- Market Events and Forecasts
- Current Treatment
- Emerging Biosimilars
- Access & Reimbursement
- Corporate Strategies

These modules can be accessed via the tabs in the report banner or via the Available Content directory.

# Biosimilars Market Events & Forecast Module

**Clarivate™ DRG** Biopharma Search within Biopharma

Home / Biosimilars / **Biosimilars** Notifications Off

At a Glance **Market Events and Forecast** Current Treatment Emerging Biosimilars Access & Reimbursement Corporate Strategies Geographic Focus: China Meet The Team

**Table of contents** Expand all

Search within Content

- Overview
- Market Event Analysis
- Forecast Methodology and General Market Assumptions
- Overview of Biosimilars Forecasts**
  - Overview of Biosimilar Forecasts**
  - Total Major-Market Reference Brand and Biosimilar Market Shares
  - Biosimilar Erosion
  - Biosimilar Erosion in the Major Markets
- Oncology
- Immunology
- Nephrology
- Endocrinology
- Respiratory
- Ophthalmology

**1. Overview of Biosimilar Forecasts**

DISPLAY All 2 1 0

Last updated 30 March 2022

This section provides a top-level overview of biosimilar erosion in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) for all biologics included in the biosimilars forecasts over the 2020-2030 forecast period.

**Key Drivers and Barriers to Biosimilars in the Major Markets**

Key Drivers of Biosimilars in the Major Markets	Key Barriers to Biosimilars in the Major Markets
<ul style="list-style-type: none"> <li>Looming biologics' patent cliff (a term that refers to the abrupt drop in an originator product's sales upon patent expiry).</li> <li>Pressure on healthcare systems to contain healthcare costs.</li> <li>Technological advances in biologics analytics and manufacturing, including lower-cost production.</li> </ul>	<ul style="list-style-type: none"> <li>Complexity of development and changing regulatory requirements.</li> <li>Physician caution adopting biosimilars, particularly for patients already receiving the reference brand.</li> <li>Relatively small savings compared with small-molecule generics.</li> <li>A current lack of pharmacy-level substitution for biologics.</li> <li>Limited presence of cohesive payer strategies to drive uptake of biosimilars at a national level (notably in the United States).</li> </ul>

Last updated: March 2022  
Source: Clarivate

**Total Major-Market Reference Brand and Biosimilar Market Shares: 2030**

100

**Downloads**

MAIN CONTENT

- Overview of Biosimilars Forecasts Full Report

ADDITIONAL FILES

- Overview of Biosimilars Forecasts Table of Contents
- All Figures
- All Tables

**Meet the Team**

Hamzah Aideed, M.Sc.  
Manager

Ask the Expert View Bio

View all Experts

Customize Your Insights

1. This module provides market events and biosimilars forecasts overall and in key therapy areas of oncology, immunology, nephrology, endocrinology, respiratory, and ophthalmology. Chapters include:
  - Market event analysis
  - Overview of biosimilars forecasts – size current market and assess historical sales performance. Includes forecasts at the geographic and drug class level.
  - Therapy area forecasts– includes quantitative market forecasts for over 40 brands and their biosimilars with sales, market share, patient share across US, EU5, and Japan markets.

# Biosimilars Market Events & Forecast Module (cont.)

**1.** Select Table of contents sections or enter word search term in search field to locate topic of interest. Word matches will be highlighted in yellow.

**2.** Reports can be downloaded by selecting the reports of interest. The accompanying PowerPoint diagrams and Excel tables can be downloaded as separate documents.

# Biosimilars Current Treatment Module

**1** Biosimilars | Current Treatment | Landscape | US/EU

**2** Oncology

## Current Treatment: Biosimilars Landscape Report 2021

Analyst: Anushree Dhar, M.Sc.  
Published: December 2021

Clarivate™ | DRG

**1.** The Current Treatment Landscape provides overarching physician perspectives on biosimilars from ~540 physicians across 6 specialties in the US and EU

**2.** Therapy area-specific analysis of physician-reported current and anticipated use of biosimilars, drivers and barriers to biosimilar use, and how physicians are choosing between biosimilars.

# Biosimilars Target Product Profiles

**1.** Select Target Product Profiles (TPP) for Oncology and Immunology. TPP uses conjoint analysis methodology to determine trade-offs across key biosimilar attributes that surveyed oncologists are willing to make when considering which biosimilar to prescribe.

**2.** Download the Target Product Profile (TPP) Simulator tool to run market simulations

The screenshot shows the 'Biosimilars' website interface. At the top, there is a navigation bar with 'Home / Biosimilars /' and a 'Notifications Off' button. Below this is a main menu with options like 'At a Glance', 'Market Events and Forecast', 'Current Treatment', 'Emerging Biosimilars', 'Access & Reimbursement', 'Corporate Strategies', 'Geographic Focus: China', and 'Meet The Team'. On the left, there is a 'Table of contents' section with a search bar and a list of categories: Overview, Biosimilars | Current Treatment | Landscape | US/EU, Oncology, Immunology, Endocrinology, and Nephrology. The 'Biosimilar Target Product Profiles (Oncology)' category is highlighted with a red box and a '1' callout. Below this, a sub-menu lists 'Target Product Profiles' with items like 'Assessing Biosimilar Development Opportunities', 'Target Product Profile Methodology', 'Attribute Importance and Part-Worth Utilities', and 'Conjoint Analysis-Based Simulation of a Market Scenario'. The main content area is titled 'Target Product Profiles' and includes a 'Last updated 23 October 2021' timestamp. The sub-header is 'Assessing Biosimilar Development Opportunities'. The text describes the methodology used, including a conjoint analysis module (ACBC) to simulate physician preference share and likelihood to prescribe user-defined target product profiles (TPPs). It mentions a market simulation performed on three hypothetical TPPs and the use of an Excel-based simulator. A list of six attributes relevant to the assessment is provided: Availability of clinical data, Inclusion in treatment guidelines, Type of manufacturer, Reimbursement restrictions, Postmarketing data, and List price. On the right, there is a 'Downloads' section with 'MAIN CONTENT' and 'ADDITIONAL FILES'. The 'ADDITIONAL FILES' section has a red box around the 'Biosimilar Target Product Profiles (Oncology) Table of Contents' link, with a '2' callout. Below this is a 'Meet the Team' section featuring Hamzah Aideed, M.Sc., Manager, with a profile picture and buttons for 'Ask the Expert' and 'View Bio'. A 'View all Experts' link is at the bottom right of the sidebar.

# Interactive target product profiles: oncology & immunology

Quantify how physicians choose between multiple biosimilars of a given reference product based on specific attributes (including price). Understand the preference share and likelihood to prescribe each biosimilar product based on modelling different clinical and non-clinical attributes.

Choose attribute levels for each biosimilar TPP

Compare up to 7 TPPs across 6 attributes

Learn preference share and likelihood to prescribe custom biosimilar TPPs versus others

RESULTS			
Preference Share	Total	United States	Europe
TPP A	20.6%	18.4%	24.9%
TPP B	12.9%	13.8%	11.2%
TPP C	29.2%	30.9%	26.0%
TPP D	37.3%	36.9%	37.9%

Likelihood to Prescribe	Total	United States	Europe
TPP A	81.0%	81.0%	81.1%
TPP B	76.5%	79.1%	71.5%
TPP C	85.1%	86.7%	82.0%
TPP D	75.5%	76.8%	73.1%

ATTRIBUTE	TPP A	TPP B	TPP C	TPP D	TPP E	TPP F	TPP G
Attribute 1	32	36	36	40			
Attribute 2	10	12	12	14			
Attribute 3	40%	60%	60%	60%			
Attribute 4	15%	15%	5%	5%			
Attribute 5	11%	11%	1%	1%			
Attribute 6	Intravenous	Intravenous	Intravenous	Oral			
Price	\$6,500.00	\$8,500.00	\$8,500.00	\$10,000.00	\$2,000.00	\$2,000.00	\$2,000.00
Include Product?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

# Emerging Biosimilars Module

**Emerging Biosimilars Landscape**

Last updated 23 June 2022

**Biosimilars Pipeline Analysis**

**Biosimilars Development Pipeline by Phase of Development**

Of all biosimilars globally, 33% are in preclinical development; 9% are in Phase I trials, 14% are in Phase III trials, 2% are filed, 4% are approved, and 35% are marketed.

Phase	Percentage
Launched	35%
Preclinical	33%
Phase III	14%
Phase I	9%
Filed	2%
Approved	4%
Clinical (unspecified phase)	2%

**1.** The Emerging Biosimilars module contains the global pipeline analysis curated by our experts to provide insights into the evolving marketplace. Analyses are updated quarterly to reflect major market events and changes in biosimilar launch dates.

**2.** There are additional supporting biosimilars launch tracking reports, however these are not part of the core Biosimilars suite.

# Biosimilars Access & Reimbursement Module

The screenshot shows the Clarivate DRG Biosimilars website. The top navigation bar includes 'Home / Biosimilars /', 'Biosimilars', and 'Notifications Off'. The main navigation menu has 'At a Glance', 'Market Events and Forecast', 'Current Treatment', 'Emerging Biosimilars', 'Access & Reimbursement', 'Corporate Strategies', 'Geographic Focus: China', and 'Meet The Team'. The 'Access & Reimbursement' section is active. On the left, a 'Table of contents' sidebar lists 'Overview' and 'Payer Insights Landscape (US-EUS)'. Two callout boxes, labeled '1' and '2', highlight 'Payer Insights Landscape (US-EUS)' and 'Access & Reimbursement Global Landscape' respectively. The main content area shows an 'Overview' section with a list of bullet points. A 'Next section' link for 'Payer Insights Landscape (US-EUS)' is visible at the bottom right of the content area.

**1.** The Payer Landscape is based on surveys of 60 US payers and interviews with 10 EU5 payers and provides insights into drivers and barriers to uptake of biosimilars, pricing expectations, and factors influencing choice among biosimilars.

**2.** The global landscape provides a primer on biosimilars policy, regulations, pricing, reimbursement in US Europe Japan and rest of world.

# Biosimilars Corporate Strategies Module

**1.** Corporate strategies provides critical competitive intelligence and actionable recommendations on how to maximize market share.

A. Strategic secondary research highlights how the leading players are seeking to defend their innovator biologics portfolios.


B. Assessment of the leading biopharma companies establishes those most at risk from biosimilar competition.

C. Profiles on the leading biosimilars companies provide insights into how market success has been achieved.

**2.** Report can be downloaded as PDF.

The screenshot displays the 'Biosimilars Corporate Strategies Module' interface. At the top, there is a navigation bar with 'Clarivate | DRG' and a search bar. Below this is a purple header with 'Biosimilars' and a 'Notifications Off' button. A secondary navigation bar contains links like 'At a Glance', 'Market Events and Forecast', 'Current Treatment', 'Emerging Biosimilars', 'Access & Reimbursement', 'Corporate Strategies', 'Geographic Focus: China', and 'Meet The Team'. The main content area is titled 'Overview' and includes a 'Table of contents' on the left with items like 'Overview', 'Key Findings', 'Biosimilar Developer Strategies', 'Reference Brand Developer Strategies', 'Biosimilar Profiles', and 'Appendix'. The 'Overview' section contains a list of bullet points detailing corporate strategies. On the right, there is a 'Downloads' section with a 'Corporate Strategies Brochure' link, a 'Meet the Team' section featuring Hamzah Aideed, M.Sc., Manager, and a 'View all Experts' link, and a 'Customize Your Insights' section. A 'Next section Key Findings' button is at the bottom right.

# Alerts Request



**1.** To request email alerts of Biosimilars report key updates, select the bell icon.

**2.** Select the disease markets that you are subscribed to, then select the “Email Preferences” checkbox, then select the “Save Settings” button.



# Support Requests

The screenshot shows the Clarivate DRG website interface. At the top, there is a navigation bar with the Clarivate logo, 'DRG', and a search bar. Below this is a purple header with 'Biosimilars' and a 'Notifications Off' button. A secondary navigation bar contains various menu items like 'At a Glance', 'Market Events and Forecast', etc. The main content area is titled 'Methodology' and features a 'Table of contents' on the left. The central text describes the 'Bottom-Up Forecast Overview: All Drug Classes Excluding G-CSFs' methodology. On the right, there are sections for 'Downloads' and 'Meet the Team'. A purple callout box on the right side of the page contains the text: '1. If you have additional questions or training/support requests, select “Ask the Expert” or “Contact Us” located under the “?” (Resources & updates) icon.' This callout points to a question mark icon in the 'Customize Your Insights' section of the sidebar.

1. If you have additional questions or training/support requests, select “Ask the Expert” or “Contact Us” located under the “?” (Resources & updates) icon.

# Appendix – Module details

# Market events & forecast details

## Module details and scope

- **Overview of biosimilars forecasts**

- Annualized sales, patient shares, and market shares from 2020-2030, segmented by region
- Forecasted biosimilar- and brand-treated patient numbers
- Interactive forecasts with graphical visualizations
- Forecasts for individual biosimilar products
- Updated biannually

- **Detailed & expanded analysis by therapy area**

- Download interactive, quantitative market forecasts for over 40 brands and their biosimilars, updated biannually.
- Access in-depth, transparent assumptions behind the market forecasts.

## Key questions answered

- What is the future MARKET SIZE for biosimilars at a regional level, class and molecule level?
- When will different biosimilars ENTER the Major Markets (i.e., U.S., EU5, and Japan) markets and how will they behave?
- How will PRICING dynamics evolve between brands and biosimilars throughout the forecast period?
- Which biosimilar marketers are anticipated to win the greatest market share when competing with multiple biosimilars referencing the same brand molecule?

# Current treatment details

## Module details and scope

- **Landscape**

- Gauge how current use of biosimilars compares across 540 physicians from 6 specialties in the United States and Europe (France and Germany).
- Assess how perceptions of the drivers and barriers to biosimilar uptake vary by specialty and region.
- Compare physicians' expected future uptake of biosimilars by specialty and region.

- **Detailed & expanded analysis by therapy area**

- Track physician-reported use of currently available biosimilars
- Understand how physicians are currently choosing between biosimilars of the same reference product.
- Understand the barriers and drivers of biosimilar use, including clinical, commercial, patient, and market access factors.
- Quantify physicians' expectations for future use of biosimilars.
- Test which biosimilar attributes will have the greatest influence on physician selection of specific biosimilars in oncology and immunology using our interactive Target Product Profiles.

## Key questions answered

- What are PHYSICIANS' CONCERNS about biosimilars and how have they changed over time?
- Will physicians SWITCH currently treated patients to a biosimilar or restrict use to new starts?
- Which factors will have the greatest INFLUENCE ON CHOICE of biosimilars

# Emerging biosimilars details

## Module details and scope

- **Landscape**

- Global pipeline analysis curated by biosimilars experts provides a clear view of the evolving competitive landscape.
- Quarterly updates highlight major pipeline changes and biosimilar launch dates for the major markets, by company.



## Key questions answered

- When will competitors launch biosimilars in the MAJOR MARKETS?
- How AWARE are physicians of a biosimilar at LAUNCH and over its first year?
- Which patients are physicians selecting to treat with the NEW BIOSIMILAR?

# Access & reimbursement details

## Module details and scope

- **Landscape**

- Primer on biosimilars policies, regulations, pricing and reimbursement in the United States, Europe, Japan, and ROW.
- Understand the strategies in place to encourage use of biosimilars at a national / regional level.

- **Detailed & expanded analysis**

- Surveys with 60 U.S. payers and interviews with 10 EU5 payers address:
  - The drivers and barriers to uptake of biosimilars.
    - Factors influencing payers' choice between multiple biosimilars.
    - Pricing expectations for biosimilars and innovator brands in a biosimilars market.
  - Current and future strategies used by U.S. and EU5 payers to drive uptake of specific biosimilars.
  - US and EU5 payer attitudes towards specific biosimilars and novel biologics.

## Key questions answered

- How are PRICING, REIMBURSEMENT AND SUBSTITUTION policies evolving for biosimilars?
- How do biosimilars REGULATIONS differ across regions?
- How will PAYERS INFLUENCE uptake of biosimilars?

# Corporate strategies details

## Module details and scope

- Addresses observed and potential strategies of biosimilar developers from target selection through to product launch, providing critical competitive intelligence, as well as actionable recommendations about how to maximize market share.
- Profiles on the leading biosimilars companies provide insights into how market success has been achieved.
- Assessment of the leading biopharma companies establishes those most at risk from biosimilar competition.
- Strategic secondary research highlights how the leading players are seeking to defend their innovator biologics portfolios.

## Key questions answered

- How have companies **ACHIEVED SUCCESS** in the biosimilars market?
- What strategies are being developed to **DEFEND AGAINST** biosimilars?



# Have a Question?

[healthcare.support@clarivate.com](mailto:healthcare.support@clarivate.com)  
[clarivate.com](https://clarivate.com)

## About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit [clarivate.com](https://clarivate.com).

---

© 2022 Clarivate. All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.